Published on Aug 4, 2020
Revision
17. New (2020) GIST drugs

RIPRETENIB

  • Ripretenib is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
  • Caution/Adverse effects: palmo-plantar erythrodysesthesia; impaired wound healing; cardiac dysfunction, HTN; New skin malignancy, teratogenic

AVAPRITINIB

  • Avapritinib is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations
  • Caution/Adverse effects: Intracranial hemorrhage; CNS effects (confusion, mood disturbance, sleep problems, hallucinations etc); teratogenic